Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.40 |
| ▸ | ARG2 | P78540 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 3/20 | 0.40 |
| ▸ | NOS1 | P29475 | 2/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 3/20 | 0.36 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | GRM8 | O00222 | 1/20 | 0.35 |
| ▸ | GRM6 | O15303 | 1/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15024999 | 1.00 | ARG1 (0.40) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL23627794 | 1.00 | ARG1 (0.40) | ARG1ARG2NOS2NOS1NOS3 | |
| Cystine SCHEMBL15844714 | 0.85 | ARG1 (0.44) | ARG1ARG2NOS2NOS1NOS3 | |
| Cystine SCHEMBL1983072 | 0.84 | PTGS1 (0.52) | ARG1ARG2NOS2NOS1NOS3 | |
| Cystine SCHEMBL7442337 | 0.84 | PTGS1 (0.52) | ARG1ARG2NOS2NOS1NOS3 | |
| Cystine SCHEMBL27890268 | 0.84 | PTGS1 (0.52) | ARG1ARG2NOS2NOS1NOS3 | |
| Cystine SCHEMBL8332360 | 0.84 | PTGS1 (0.50) | ARG1ARG2NOS2NOS1NOS3 | |
| Cystine SCHEMBL10224 | 0.84 | PTGS1 (0.50) | ARG1ARG2NOS2NOS1NOS3 | |
| Cystine SCHEMBL21114356 | 0.84 | PTGS1 (0.50) | ARG1ARG2NOS2NOS1NOS3 | |
| Cystine SCHEMBL5018669 | 0.84 | PTGS1 (0.50) | ARG1ARG2NOS2NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119139329-A | Preparation of brinzdofovir | 应急生物防御行动兰辛有限责任公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-118416082-A | Preparation of brinzdofovir | 应急生物防御行动兰辛有限责任公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20080153891-A1 | SYNERGISTIC ANTI-CANCER COMPOSITIONS | THE ARIZONA BOARD OF REGENTS (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080146653-A1 | SYNERGISTIC ANTI-CANCER COMPOSITIONS | THE ARIZONA BOARD OF REGENTS (US) | 2008-06-19 | — | — | US | disclosed |
| WO-2008063778-A2 | SYNERGISTIC COMBINATIONS OF ANTINEOPLASTIC THIOL-BINDING MITOCHONDRIAL OXIDANTS AND ANTINEOPLASTIC CORTICOSTERIODS FOR THE TREATMENT OF CANCER | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008033807-A2 | SYNERGISTIC COMBINATIONS OF ANTINEOPLASTIC THIOL-BINDING MITOCHONDRIAL OXIDANTS AND ANTINEOPLASTIC PROTEASOME INHIBITORS FOR THE TREATMENT OF CANCER | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2008-03-20 | — | — | WO | disclosed |
| CN-1889943-A | Synergistic anti-cancer compounds | UNIV ARIZONA (US) | 2007-01-03 | — | — | CN | disclosed |
| EP-1691801-A2 | SYNERGISTIC ANTI-CANCER COMPOSITIONS | The Arizona Board of Regents on Behalf of the University of Arizona (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050176696-A1 | Synergistic anit-cancer compounds | REGENTS OF THE UNIVERSITY OF ARIZONA (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005055952-A2 | SYNERGISTIC ANTI-CANCER COMPOSITIONS | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153891-A1 | SYNERGISTIC ANTI-CANCER COMPOSITIONS | POLRMT, SSBP1, TK2 | ARG1 4003/4885ARG2 471/4885NOS2 3114/4885 |
| US-20080146653-A1 | SYNERGISTIC ANTI-CANCER COMPOSITIONS | POLRMT, SSBP1, TK2 | ARG1 4003/4885ARG2 471/4885NOS2 3114/4885 |
| US-20050176696-A1 | Synergistic anit-cancer compounds | POLRMT, SSBP1, DDIT3 | ARG1 3209/4885ARG2 393/4885NOS2 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.